EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
…, O Rouvière, IG Schoots, D Tilki, T Wiegel… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
… Thomas Wiegel receives company speaker honoraria from Astellas, Takeda, Hexal, Ipsen,
Janssen-Cilac, and Ferring. Philip Cornford is a company consultant for Astellas, Ipsen and …
Janssen-Cilac, and Ferring. Philip Cornford is a company consultant for Astellas, Ipsen and …
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013
…, T van der Kwast, M Mason, V Matveev, T Wiegel… - European urology, 2014 - Elsevier
Context The most recent summary of the European Association of Urology (EAU) guidelines
on prostate cancer (PCa) was published in 2011. Objective To present a summary of the …
on prostate cancer (PCa) was published in 2011. Objective To present a summary of the …
EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer
…, O Rouvière, IG Schoots, D Tilki, T Wiegel… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer
…, TH van der Kwast, O Rouvière, T Wiegel… - European urology, 2017 - Elsevier
… Wiegel has received company speaker honoraria from Astellas, Takeda, Hexal, Ipsen,
Janssen-Cilac, and Ferring. N. Mottet has received grant and research support from Takeda …
Janssen-Cilac, and Ferring. N. Mottet has received grant and research support from Takeda …
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease
…, N Mottet, HP Schmid, T van der Kwast, T Wiegel… - European urology, 2011 - Elsevier
OBJECTIVE: Our aim was to present a summary of the 2010 version of the European
Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of clinically …
Association of Urology (EAU) guidelines on the screening, diagnosis, and treatment of clinically …
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer
…, T van der Kwast, M Mason, V Matveev, T Wiegel… - European urology, 2014 - Elsevier
Objective To present a summary of the 2013 version of the European Association of Urology
(EAU) guidelines on the treatment of advanced, relapsing, and castration-resistant prostate …
(EAU) guidelines on the treatment of advanced, relapsing, and castration-resistant prostate …
[PDF][PDF] Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative …
T Wiegel, D Bottke, U Steiner, A Siegmann, R Golz… - Clinical …, 2007 - academia.edu
Purpose Local failure after radical prostatectomy (RP) is common in patients with cancer
extending beyond the capsule. Two randomized trials demonstrated an advantage for adjuvant …
extending beyond the capsule. Two randomized trials demonstrated an advantage for adjuvant …
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study …
…, AA Brandes, JC Tonn, O Schnell, T Wiegel… - The lancet …, 2014 - thelancet.com
Background Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2
trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in …
trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in …
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer
…, HP Schmid, T Van der Kwast, T Wiegel… - Actas Urológicas …, 2011 - Elsevier
Objectives Our aim is to present a summary of the 2010 version of the European Association
of Urology (EAU) guidelines on the treatment of advanced, relapsing, and castration-…
of Urology (EAU) guidelines on the treatment of advanced, relapsing, and castration-…